Nattopharmas’s strategy to build value for its shareholders and other stakeholders is based on the following key elements:
Continue Investing in R&D and Patens of Vitamin K2
Several studies demonstrate the great health benefits of Vitamin K2, especially for bone and cardiovascular health, as well as for children’s health. NattoPharma has a long-term clinical program for MenaQ7® to investigate aspects of this very important compound in health and disease. NattoPharma’s dedication to this lies in partnerships with world experts and marketing partners from all over the world. We strongly focus on Intellectual Property Rights and are presently securing IP for use of MK-7 in interesting clinical fields supported by studies to make further documentation of the positive effects.
Incresing Global Understanding, & Awareness of Vitamin K2’s Health Benefits
Vitamin K2 is the last recognized deficiency in the vitamin market. Consumer knowledge and recognition of the importance of rectifying this deficiency is building, thanks greatly to NattoPharma’s efforts, but there is still a long way to go. We will continue to focus our PR efforts to increase the knowledge of Vitamin K2 for both key stakeholder and the general market.
Actively Engaging Leading Global Nutrition & Food Companies
NattoPharma offers superior Vitamin K2 to customers in the health care, supplement and functional food markets. Important food companies are primarily dairy enterprises; however, we also recognize the importance of companies producing non-alcoholic beverages and bakery products. With such firms positioned as driving forces for healthy foods and drinks relevant to NattoPharma, the company has cultivated its products and services to make MenaQ7® Vitamin K2 as MK-7 accessible to the nutraceutical industry and beyond. Our offer caters to the needs of any finished product manufacturer, and we are eager to discuss the solution that will make their end goal achievable.